Loading…
← CockpitCompetitor Analysis › 600771.SS GuangYuYuan Chinese Herbal Medicine Co., Ltd. Class AOpen in the cockpit ↗

GuangYuYuan Chinese Herbal Medicine Co., Ltd. Class A600771.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum neutral 43
Mkt cap
$866M
US dollars, full cap
Free float
85%
of shares outstanding
$/day
$14.4M
20-day average traded
Fwd P/E
38.3×
forward earnings
ROIC−WACC
-4.4 pp
WACC 10.0%
Hurdle
+28 pp
Req g minus delivered
Next earnings
156 days
23 Apr 2027
Close · CNYCN¥11.92
1D-2.3%
1W-4.6%
1M-14.6%
3M-16.7%
6M-25.7%
YTD-33.7%
1Y-38.2%
ATR %2.9%
52w lowhigh41.6% off high

What GuangYuYuan Chinese Herbal Medicine does

Employees: 1,744

GuangYuYuan Chinese Herbal Medicine at a glance

Size GuangYuYuan Chinese Herbal Medicine (600771.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $866M, the 2440th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.92 on 18 Nov 2026.

Performance Over six months the shares fell 25.7%, against -23.0% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 19 in its peer set.

Growth Revenue fell 5.5% over the last twelve months (peer median +3.6%); the operating margin is 4.5% (peer median -0.8%).

Valuation It trades at 38.3× forward earnings against a peer median of 24.7× (most expensive of 7).

Price implies For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +28 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.4 points below its cost of capital (10.0% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026600771.SS 76Peer median 76
Six months, rebased to 100: GuangYuYuan Chinese Herbal Medicine against the median of its 20 peers (local-currency closes).

GuangYuYuan Chinese Herbal Medicine financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.31BCN¥1.35BCN¥1.20BCN¥1.27BCN¥1.12B
Revenue growth—+12%-5%+14%—
Gross profitCN¥891MCN¥882MCN¥861MCN¥899MCN¥734M
EBITDAn/aCN¥170MCN¥144MCN¥154M-CN¥187M
Net incomeCN¥63.2MCN¥63.0MCN¥74.5MCN¥90.1M-CN¥250M
Free cash flowCN¥216MCN¥191MCN¥103MCN¥214MCN¥246M
Capital expenditureCN¥7.60MCN¥6.24MCN¥8.78MCN¥2.51MCN¥8.67M
Total debtCN¥41.4MCN¥63.0MCN¥77.8MCN¥333MCN¥564M

Quarterly statements and history in the cockpit →

GuangYuYuan Chinese Herbal Medicine competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%006120PHARMSANOFICONR4521CRVS069620086450688176688621000597AKTS6885533002670008136032290020822595IMTX600771.SS6-month return →1-month return →
Up and to the right = strong over both horizons. GuangYuYuan Chinese Herbal Medicine is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%10×20×30×40×PHARMSANOFICONR4521069620086450688621600771.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. GuangYuYuan Chinese Herbal Medicine is the large dot.

Capital: growth delivered against growth the price implies

-40%-20%0%+20%-40%-20%0%20%PHARMSANOFICONR086450000597688553002082600771.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. GuangYuYuan Chinese Herbal Medicine is the large dot.

GuangYuYuan Chinese Herbal Medicine competitors and peer comparison

How GuangYuYuan Chinese Herbal Medicine compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

GuangYuYuan Chinese Herbal Medicine against its 20 peers (data as of 18 Nov 2026)
Measure600771.SSPeer medianRank in peer set
1-month return-14.6%-10.5%7th lowest of 21
6-month return-25.7%-23.0%10th highest of 19
Distance from 52-week high-41.6%-43.7%10th highest of 21
Revenue growth (TTM)-5.5%+3.6%7th lowest of 19
Operating margin4.5%-0.8%7th highest of 19
Forward P/E38.3×24.7×most expensive of 7
Growth the price implies (Req g, 7 yrs)31.7%10.1%most demanding of 7
Growth delivered (Del g)+4.2%+4.9%4th highest of 7
Hurdle (Req g minus delivered)+27.5 pp-5.9 pp2nd most demanding of 7
ROIC minus cost of capital-4.4 pp-2.3 pp6th lowest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
GuangYuYuan Chinese Herbal Medicine 600771.SSChina$866M-26%-6%5%38.3×31.7%+4.2%
SK Discovery 006120.KSSouth Korea$866M+25%+24%3%n/an/an/a
Pharming PHARM.ASNetherlands$867M-6%+2%9%34.9×2.4%+12.4%
Sanofi Consumer Healthcare India SANOFICONR.NSIndia$869M-26%+23%36%28.1×17.7%+22.7%
City Therapeutics CTYUnited States$861Mn/a+388%-442%n/an/an/a
Kaken Pharmaceutical 4521.TJapan$860M-8%+5%10%21.4×n/an/a
Corvus Pharmaceuticals CRVSUnited States$860M-16%n/an/an/an/an/a
Daewoong Pharm 069620.KSSouth Korea$856M-33%+9%12%9.0×n/an/a
DongKook Pharmaceutical 086450.KSSouth Korea$855M+9%+13%10%14.0×-4.2%+10.6%
Jiangsu Yahong Meditech 688176.SSChina$854M-20%+15%-172%n/an/an/a
Latigo Biotherapeutics LTGOUnited States$882Mn/an/an/an/an/an/a
Beijing Sun-Novo Pharmaceutical Research 688621.SSChina$849M-8%-1%-2%29.0×n/an/a
Northeast Pharmaceutical 000597.SZChina$895M-14%-6%3%n/a-7.6%-0.7%
Aktis Oncology AKTSUnited States$895M-15%+337%-837%n/an/an/a
Sichuan Huiyu Pharmaceutical 688553.SSChina$904M-28%+14%7%n/a19.4%-6.0%
Hunan Er-Kang Pharmaceutical 300267.SZChina$829M-40%-14%-29%n/an/an/a
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%n/an/an/a
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%n/an/an/a
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%n/a27.7%-39.5%
Genfleet Therapeutics (Shanghai) 2595.HKHong Kong$912M-42%-55%-457%n/an/an/a
Immatics IMTXUnited States$913M-46%-44%-589%n/an/an/a

Questions

Which companies are GuangYuYuan Chinese Herbal Medicine's closest peers?
The cockpit's peer set: SK Discovery (006120.KS), Pharming (PHARM.AS), Sanofi Consumer Healthcare India (SANOFICONR.NS), City Therapeutics (CTY), Kaken Pharmaceutical (4521.T), Corvus Pharmaceuticals (CRVS), Daewoong Pharm (069620.KS), DongKook Pharmaceutical (086450.KS).
Is GuangYuYuan Chinese Herbal Medicine expensive compared with its peers?
On forward p/e it trades at 38.3× against a peer median of 24.7×, most expensive of 7 in its peer set. For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +28 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has GuangYuYuan Chinese Herbal Medicine stock performed?
Over six months to 18 Nov 2026 the shares returned -25.7% against -23.0% for the median peer; over one year -38.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.